Yao et al. (2022) constructed a synergistic antitumor platform (designated BMS/RA@CC liposome) using CT26 cancer cell biomimetic nanoparticles combined with chemotherapeutic agents (RAV) and PD-1/PD-L1 blocking inhibitors (BMS-202) to significantly enhance antitumor immunity Figure 2. Meanwhile, this study mainly used cyclic peptide RA-V as a chemotherapeutic drug to directly kill tumor cells (Xu et al., 2021), and BMS-202 as an anti-PD drug to induce anti-tumor immune responses (Mikhail et al., 2022), and was co-encapsulated in a pH-sensitive nanosystems. This evidence concerns the gene CD274 and neoplasm.